TQ-A3334

TQ-A3334 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for TQ-A3334, covering 2019-12-16 to 2025-11-26. Get the full timeline:

Most recent: Clinical Trial Update: Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection [Phase 2]

See pricing